Clinical Validity Consulting
The Clinical Validity Gap in Real-World Evidence
The Problem
Real-world evidence companies routinely ship cardiovascular studies that contain foundational clinical errors invisible to data scientists and statisticians:
- Phenotyping misclassification — algorithms built from claims and EHR data encode billing behavior rather than clinical diagnosis, systematically misclassifying patients with atrial fibrillation, heart failure, and acute coronary syndromes
- Medication discontinuation errors — gap-based assumptions ignore prescription refill patterns, sample dispensation, and formulary switching, producing artificially elevated discontinuation rates
- Outcome misclassification — composite endpoints conflate events with meaningfully different mechanisms and clinical significance
- Systematic structural errors — embedded in the most common analytical pipelines in the industry, not edge cases
Why It Matters Now
The FDA's Real-World Evidence Program and the EMA's evolving framework have materially raised the bar for methodological transparency and clinical defensibility:
- Regulatory scrutiny — FDA and EMA now question phenotype construction, exposure ascertainment, and outcome adjudication that most RWE teams cannot adequately answer without physician-scientist input
- Flawed conclusions propagate — uncorrected studies enter clinical practice guidelines, formulary decisions, and health policy before errors are caught
- Structural bias — a phenotype that misclassifies 15% of patients produces a structurally biased effect estimate that can reverse the direction of a treatment comparison
What AI-HEART Lab Provides
AI-HEART Lab brings physician-scientist oversight directly into the RWE infrastructure review process. Engagements typically span three domains:
Clinical Validation of Phenotyping Algorithms
- Review logic underlying case identification for cardiovascular conditions
- Cross-reference against published validation studies and apply clinical reasoning to edge-case patients
- Recommend specific code additions, exclusions, or sensitivity analyses to align phenotypes with clinical diagnosis
Endpoint Adjudication Consulting
- Ensure composite endpoints are clinically coherent
- Verify each component is ascertained by the most defensible available method
- Meet adjudication standards expected by JACC, Circulation, and the European Heart Journal
Study Design Review
- Population selection and comparator definition
- Confounding variable specification and time-zero alignment
- Corrections cost hours upstream — months downstream
A Track Record That Speaks to the Work
Dr. Rahul Chaudhary, AI-HEART Lab's founder, is a staff cardiologist and physician-scientist trained at Johns Hopkins, Mayo Clinic, and the University of Pittsburgh. His research record spans 150+ peer-reviewed publications (h-index 26; 2,838 citations) with 18 international guideline citations from the AHA, ESC, ACC/AHA, SCAI, and HRS — including work published in Circulation, the Journal of the American College of Cardiology, and the European Heart Journal. He currently serves as Chair of the Endpoint Adjudication Committee for a multinational prospective cardiovascular outcomes trial and as Guest Editor for the Journal of Clinical Medicine. That combination — a physician-scientist's publication record, active peer review for the leading cardiovascular journals, and graduate training in machine learning at Georgia Tech — is the basis on which AI-HEART Lab provides oversight that holds up under regulatory and editorial scrutiny. If your study has a cardiovascular endpoint and you want to ensure the methodology is clinically defensible, the conversation starts here.